Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated yesterdaySource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1990 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOXAN PWS FOR INJ 1000MG/VIAL (DIN 00602833) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in… | DIN00602833 | withdrawnsource: Cancelled Post Marketsince Oct 17, 2008 | health-canada-dpd |
| Dec 31, 1990 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as RHEUMATREX TAB 2.5MG (DIN 00874132) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN00874132 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2000 | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 1990 | Leuprolide | FDA US | cancer not stated in this record | Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. • In combination with a… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 4, 1990 | Cytarabine | FDA US | cancer not stated in this record | Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1989 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TAMOX TAB 20MG (DIN 00812390) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN00812390 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 26, 1989 | Leuprolide | FDA US | Malignant Prostate Neoplasm | LUPRON DEPOT 7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1988 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLATINOL AQ INJ 1MG/ML (DIN 00788740) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN00788740 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 16, 1988 | Tretinoin | FDA US | cancer not stated in this record | Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this… | ORIGNDA019049 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 8, 1988 | Megestrol | FDA US | Breast Carcinoma | Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent,… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 19, 1988 | Vincristine | FDA US | cancer not stated in this record | Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 3, 1988 | Sulindac | FDA US | cancer not stated in this record | Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1987 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEGACE (DIN 00731323) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database — see… | DIN00731323 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 14, 1987 | Ifosfamide | FDA US | Malignant Testicular Neoplasm | Ifosfamide for Injection is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 29, 1987 | Vinblastine | FDA US | cancer not stated in this record | I. Frequently Responsive Malignancies • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma •… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1986 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMOFEN 20 (DIN 01926632) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database —… | DIN01926632 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| ORIGNDA020011 |
| approved |
| openfda |
| ORIGANDA071868 |
| approved |
| openfda |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 31, 1989 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TAMOX TAB 10MG (DIN 00812404) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN00812404 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1989 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUPRON DEPOT (DIN 00836273) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database… | DIN00836273 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1989 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION (DIN 00012882) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN00012882 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1989 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMONE TAB 20MG (DIN 00810452) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN00810452 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| Dec 31, 1989 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMONE TAB 10MG (DIN 00810444) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN00810444 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| Dec 31, 1989 | Interferon Alpha-2a | Health Canada CA | cancer not stated in this record | Marketed in Canada as ROFERON-A SOL INJ 3MILLION IU/VIAL (DIN 00812501) under ATC L03AB04 INTERFERON ALFA-2A. Indications are not published… | DIN00812501 | withdrawnsource: Cancelled Post Marketsince Aug 25, 1997 | health-canada-dpd |
| Dec 31, 1989 | Interferon Alpha-2a | Health Canada CA | cancer not stated in this record | Marketed in Canada as ROFERON A SOLN INJ 6 MILLION (DIN 00812498) under ATC L03AB04 INTERFERON ALFA-2A. Indications are not published in… | DIN00812498 | withdrawnsource: Cancelled Post Marketsince Aug 26, 1997 | health-canada-dpd |
| Dec 31, 1989 | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFEX PWS 2G/VIAL (DIN 00797235) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product… | DIN00797235 | withdrawnsource: Cancelled Post Marketsince Aug 14, 1997 | health-canada-dpd |
| Dec 31, 1989 | Vincristine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINCRISTINE SULFATE INJ 5MG/VIAL USP (DIN 00690317) under ATC L01CA02 VINCRISTINE. Indications are not published in… | DIN00690317 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| Dec 31, 1989 | Vincristine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINCRISTINE SULFATE INJ 1MG/ML USP (DIN 00726575) under ATC L01CA02 VINCRISTINE. Indications are not published in the… | DIN00726575 | withdrawnsource: Cancelled Post Marketsince Aug 10, 1999 | health-canada-dpd |
| Dec 31, 1989 | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFEX PWS 1GM/VIAL (DIN 00797227) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product… | DIN00797227 | withdrawnsource: Cancelled Post Marketsince Apr 9, 2001 | health-canada-dpd |
| Dec 31, 1989 | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFEX PWS 3GM/VIAL (DIN 00808601) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product… | DIN00808601 | withdrawnsource: Cancelled Post Marketsince Jul 11, 2002 | health-canada-dpd |
| Dec 31, 1989 | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PARAPLATIN-AQ INJ 10MG/ML (DIN 00788759) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug… | DIN00788759 | withdrawnsource: Cancelled Post Marketsince Jul 30, 2007 | health-canada-dpd |
| Dec 29, 1989 | Goserelin | FDA US | cancer not stated in this record | The management of endometriosis • Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding | ORIGNDA019726 | approved | openfda |
| Dec 29, 1989 | Goserelin | FDA US | Malignant Breast Neoplasm | Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women | ORIGNDA019726 | approved | openfda |
| Dec 29, 1989 | Goserelin | FDA US | Prostate Carcinoma | Palliative treatment of advanced carcinoma of the prostate | ORIGNDA019726 | approved | openfda |
| Dec 29, 1989 | Goserelin | FDA US | Prostate Carcinoma | Use in combination with flutamide for the management of locally confined carcinoma of the prostate | ORIGNDA019726 | approved | openfda |
| ORIGNDA019732 |
| approved |
| openfda |
| withdrawnsource: Cancelled Post Marketsince Jul 30, 2001 |
| health-canada-dpd |
| Dec 31, 1988 | Buserelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUPREFACT INTRANASAL SOLUTION 1MG/ML (DIN 00680036) under ATC L02AE01 BUSERELIN. Indications are not published in the… | DIN00680036 | withdrawnsource: Cancelled Post Marketsince Aug 29, 1996 | health-canada-dpd |
| Dec 31, 1988 | Buserelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUPREFACT INJ 1MG/ML (DIN 00680028) under ATC L02AE01 BUSERELIN. Indications are not published in the Drug Product… | DIN00680028 | withdrawnsource: Cancelled Post Marketsince Aug 25, 1998 | health-canada-dpd |
| Dec 31, 1988 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRIAMYCIN RDF INJ 150MG/VIAL (DIN 00768766) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug… | DIN00768766 | withdrawnsource: Cancelled Post Marketsince Sep 10, 1996 | health-canada-dpd |
| approved |
| openfda |
| ORIGANDA072423 |
| approved |
| openfda |
| ORIGANDA071484 |
| approved |
| openfda |
| Apr 7, 1988 | Methotrexate | FDA US | cancer not stated in this record | Efficacy supplement 1988-04-07 (see label) | SUPPLNDA011719 | approved | openfda |
| ORIGANDA071795 |
| approved |
| openfda |
| withdrawnsource: Cancelled Post Marketsince Mar 9, 2009 |
| health-canada-dpd |
| Dec 23, 1987 | Doxorubicin | FDA US | cancer not stated in this record | for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast… | ORIGNDA050629 | approved | openfda |
| Dec 23, 1987 | Doxorubicin | FDA US | Malignant Breast Neoplasm | as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of… | ORIGNDA050629 | approved | openfda |
| ORIGNDA019763 |
| approved |
| openfda |
| ORIGANDA089515 |
| approved |
| openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Choriocarcinoma | Choriocarcinoma resistant to other chemotherapeutic agents | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Kaposi Sarcoma | Kaposi’s sarcoma | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Mycosis Fungoides | Mycosis fungoides (advanced stages) | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Hodgkin Lymphoma | Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Cyclophosphamide | FDA US | cancer not stated in this record | Efficacy supplement 1987-04-29 (see label) | SUPPLNDA012141 | approved | openfda |
| withdrawnsource: Cancelled Post Marketsince Jan 14, 2011 |
| health-canada-dpd |
| Dec 31, 1986 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMOFEN 10 (DIN 01926624) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database —… | DIN01926624 | withdrawnsource: Cancelled Post Marketsince Jan 11, 2011 | health-canada-dpd |
| Dec 31, 1986 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOSAR (DIN 00646318) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see… | DIN00646318 | withdrawnsource: Cancelled Post Marketsince Jul 4, 2025 | health-canada-dpd |
| Dec 31, 1986 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTOSAR (DIN 00646296) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see… | DIN00646296 | withdrawnsource: Cancelled Post Marketsince Jul 4, 2025 | health-canada-dpd |
| Dec 31, 1986 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJ 1MG/ML (DIN 00692743) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN00692743 | withdrawnsource: Cancelled Post Marketsince Aug 13, 1998 | health-canada-dpd |
| Dec 31, 1986 | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PARAPLATIN INJ 150MG/VIAL (DIN 00680060) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug… | DIN00680060 | withdrawnsource: Cancelled Post Marketsince Sep 9, 1996 | health-canada-dpd |
| Dec 31, 1986 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A INJ 10000000UNIT/VIAL (DIN 00705926) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in… | DIN00705926 | withdrawnsource: Cancelled Post Marketsince Jul 22, 1999 | health-canada-dpd |
| Dec 31, 1986 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A INJ 5000000UNIT/VIAL (DIN 00705918) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in… | DIN00705918 | withdrawnsource: Cancelled Post Marketsince Jul 22, 1999 | health-canada-dpd |